Purple Biotech (PPBT) Common Equity (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Common Equity data on file, last reported at $9.7 million in Q1 2026.

• On a quarterly basis, Common Equity fell 70.44% year-over-year to $9.7 million in Q1 2026; TTM through Mar 2026 was $9.7 million, a 70.44% decrease from a year earlier, with the FY2025 full-year figure at $9.7 million, up 137.57% from the prior year.
• Common Equity for Q1 2026 stood at $9.7 million, roughly flat from $9.7 million in the prior quarter.
• Over the last five years, Common Equity for PPBT reached as high as $58.3 million in Q1 2022 and fell as low as -$25.7 million in Q4 2024.
• Historically, Common Equity has averaged $32.8 million across 5 years, with a median of $32.8 million in 2025.
• Across the five-year window, Common Equity plunged 174.97% in 2024 and soared 137.57% in 2025, its largest moves.
• Year by year, Common Equity stood at $47.1 million in 2022, then dropped by 27.18% to $34.3 million in 2023, then plunged by 174.97% to -$25.7 million in 2024, then surged by 137.57% to $9.7 million in 2025, then increased by 0.05% to $9.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $9.7 million in Q1 2026, $9.7 million in Q4 2025, and $32.8 million in Q3 2025.